CompletedPhase 1NCT02715570

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

Studying Allergic bronchopulmonary aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pulmocide Ltd
Principal Investigator
Muna Albayaty, MBChB, FFPM, MSc
cro
Intervention
PC945 - single doses(drug)
Enrollment
29 enrolled
Eligibility
18-65 years · All sexes
Timeline
20172018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02715570 on ClinicalTrials.gov

Other trials for Allergic bronchopulmonary aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Allergic bronchopulmonary aspergillosis

← Back to all trials